

Nora Butta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9384454/publications.pdf>

Version: 2024-02-01

67
papers

624
citations

566801

15
h-index

676716

22
g-index

67
all docs

67
docs citations

67
times ranked

957
citing authors

#	ARTICLE	IF	CITATIONS
1	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. <i>Archivos De Bronconeumologia</i> , 2022, 58, 117-124.	0.4	20
2	Acquired Haemophilia A: A 15-Year Single-Centre Experience of Demography, Clinical Features and Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 2721.	1.0	3
3	Novel Therapies to Address Unmet Needs in ITP. <i>Pharmaceuticals</i> , 2022, 15, 779.	1.7	7
4	COVID-19 Vaccines and Autoimmune Hematologic Disorders. <i>Vaccines</i> , 2022, 10, 961.	2.1	23
5	Pro-apoptotic properties and mitochondrial functionality in platelet-like-particles generated from low Aspirin-incubated Meg-01 cells. <i>Platelets</i> , 2021, 32, 1063-1072.	1.1	4
6	COVID-19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. <i>Haemophilia</i> , 2021, 27, e137-e139.	1.0	11
7	Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021, 192, 973-977.	1.2	18
8	Impact of COVID-19 Pandemic on Patients with Immune Thrombocytopaenia. <i>Medicina (Lithuania)</i> , 2021, 57, 219.	0.8	1
9	The Importance of Platelet Glycoside Residues in the Haemostasis of Patients with Immune Thrombocytopaenia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1661.	1.0	8
10	Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6907.	1.8	10
11	Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 1021-1021.	0.6	0
12	Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests. <i>Blood</i> , 2021, 138, 4235-4235.	0.6	0
13	Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay. <i>Blood</i> , 2021, 138, 4233-4233.	0.6	0
14	Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 3158-3158.	0.6	1
15	Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency. <i>Blood</i> , 2021, 138, 1046-1046.	0.6	0
16	Next-generation sequencing for the diagnosis of MYH9: Predicting pathogenic variants. <i>Human Mutation</i> , 2020, 41, 277-290.	1.1	30
17	Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies. <i>Journal of Clinical Medicine</i> , 2020, 9, 3297.	1.0	8
18	Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. <i>Frontiers in Medicine</i> , 2020, 7, 576558.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience. <i>Haemophilia</i> , 2020, 26, e247-e249.	1.0	5
20	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. <i>Haematologica</i> , 2020, 105, 1948-1956.	1.7	7
21	Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. <i>Haemophilia</i> , 2020, 26, 773-778.	1.0	18
22	Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation. <i>British Journal of Haematology</i> , 2020, 189, 943-953.	1.2	27
23	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. <i>Thrombosis and Haemostasis</i> , 2019, 119, 645-659.	1.8	31
24	Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein. <i>Blood</i> , 2019, 134, 4929-4929.	0.6	2
25	Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus. <i>Blood</i> , 2019, 134, 1141-1141.	0.6	1
26	Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments. <i>Blood</i> , 2019, 134, 1089-1089.	0.6	1
27	Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. <i>Blood</i> , 2019, 134, 1118-1118.	0.6	0
28	Factors Involved in Maintaining Haemostasis in Patients with Myelodysplastic Syndrome. <i>Thrombosis and Haemostasis</i> , 2018, 47, 734-744.	1.8	1
29	Immune thrombocytopenia "in defence of the platelet count. Response to Hill. <i>British Journal of Haematology</i> , 2018, 182, 130-131.	1.2	0
30	Platelet Protein Glycosylation in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 2437-2437.	0.6	2
31	Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. <i>Blood</i> , 2018, 132, 5048-5048.	0.6	0
32	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. <i>Aids</i> , 2016, 30, 1141-1142.	1.0	7
33	Procoagulant profile in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2016, 175, 925-934.	1.2	42
34	In vitro thromboelastometric evaluation of the efficacy of frozen platelet transfusion. <i>Thrombosis Research</i> , 2015, 136, 348-353.	0.8	9
35	Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 621-628.	1.5	29
36	Effect of thrombopoietin receptor agonists on a proliferation-inducing ligand (<sc>APRIL</sc>) plasma levels in patients with immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 674-676.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2014, 112, 65-72.	1.8	28
38	Pharmacokinetics of Multiple Doses of rFVIIa in Patients with Hemophilia With and Without Inhibitors. <i>Blood</i> , 2014, 124, 2824-2824.	0.6	20
39	Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin. <i>Blood</i> , 2014, 124, 1462-1462.	0.6	0
40	Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 81.	1.2	20
41	Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. <i>Thrombosis and Haemostasis</i> , 2013, 109, 909-919.	1.8	13
42	Procoagulant Status In Patients With Immune Thrombocytopenia. <i>Blood</i> , 2013, 122, 3528-3528.	0.6	1
43	Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia. <i>Blood</i> , 2013, 122, 1083-1083.	0.6	0
44	Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. <i>Thrombosis and Haemostasis</i> , 2012, 107, 88-98.	1.8	25
45	Treatment of Primary Immune Thrombocytopenia with Thrombopoietin Receptor Agonists: Effect On Platelet Function and Plasma Thrombin Generation. <i>Blood</i> , 2012, 120, 1089-1089.	0.6	0
46	Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center. <i>Blood</i> , 2012, 120, 4658-4658.	0.6	0
47	Microparticle-Associated Thrombogenic Mechanism Might Compensate Bleeding Tendency in Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2012, 120, 2821-2821.	0.6	0
48	Haemostasis Assessed by Rotational Thromboelastometry and Thrombin Generation Test in Behcet's Disease Patients,. <i>Blood</i> , 2011, 118, 3313-3313.	0.6	0
49	Platelet Functions and Risk Prognosis in Myelodysplastic Syndromes,. <i>Blood</i> , 2011, 118, 3806-3806.	0.6	0
50	Increased Microparticle-Linked Procoagulant Activity In Patients with Primary Immune Thrombocytopenia.. <i>Blood</i> , 2010, 116, 3707-3707.	0.6	0
51	Platelet Apoptosis and Agonist Mediated Activation In Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 1866-1866.	0.6	0
52	Variations in platelet protein associated with arterial thrombosis. <i>Thrombosis Research</i> , 2008, 122, 640-647.	0.8	22
53	Type I Glanzmann thrombasthenia caused by an apparently silent $\beta 3$ mutation that results in aberrant splicing and reduced $\beta 3$ mRNA. <i>Thrombosis and Haemostasis</i> , 2005, 93, 897-903.	1.8	15
54	α -Adrenergic-mediated activation of human reconstituted fibrinogen receptor (integrin α IIb β 3) in Chinese hamster ovary cells. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1368-1376.	1.8	5

#	ARTICLE	IF	CITATIONS
55	A variant thrombasthenic phenotype associated with compound heterozygosity of integrin α _{IIb} β ₃ -subunit: (Met124Val) α _{IIb} β ₃ alters the subunit dimerization rendering a decreased number of constitutive active α _{IIb} β ₃ receptors. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1377-1386.	1.8	11
56	Disruption of the α _{IIb} β ₃ 663-687 disulfide bridge confers constitutive activity to α _{IIb} β ₃ integrins. <i>Blood</i> , 2003, 102, 2491-2497.	0.6	42
57	Agonist-induced aggregation of Chinese hamster ovary cells coexpressing the human receptors for fibrinogen (integrin α _{IIb} β ₃) and the platelet-activating factor: dissociation between adhesion and aggregation. <i>Blood</i> , 2002, 99, 2819-2827.	0.6	9
58	Competition between normal [674C] and mutant [674R]GPIIb subunits: role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes. <i>Blood</i> , 2001, 97, 2640-2647.	0.6	15
59	Cloning and functional characterization of the 5' flanking region of the human mitochondrial malic enzyme gene. <i>FEBS Journal</i> , 2001, 268, 3017-3027.	0.2	6
60	A 1063G→A mutation in exon 12 of glycoprotein (GP)IIb associated with a thrombasthenic phenotype: mutation analysis of [324E]GPIIb. <i>British Journal of Haematology</i> , 2000, 111, 965-973.	1.2	4
61	A 1063GA mutation in exon 12 of glycoprotein (GP)IIb associated with a thrombasthenic phenotype: mutation analysis of [324E]GPIIb. <i>British Journal of Haematology</i> , 2000, 111, 965-973.	1.2	3
62	Molecular Cloning and Functional Characterization of the Human Cytosolic Malic Enzyme Promoter: Thyroid Hormone Responsiveness. <i>DNA and Cell Biology</i> , 1997, 16, 533-544.	0.9	17
63	Role of Ca ²⁺ and protein kinase C in the receptor-mediated activation of Na ⁺ /H ⁺ exchange in isolated liver cells. <i>Biochemical Journal</i> , 1997, 325, 631-636.	1.7	16
64	Modulation of the hepatic α ₁ -adrenoceptor responsiveness by colchicine: dissociation of free cytosolic Ca ²⁺ -dependent and independent responses. <i>British Journal of Pharmacology</i> , 1996, 118, 1797-1805.	2.7	6
65	Effect of phenylarsine oxide on hepatic α ₁ -adrenoceptor responsiveness. dissociation between ionotropic and metabolic responses. <i>Life Sciences</i> , 1995, 57, 1299-1307.	2.0	0
66	Characterization of the α ₁ -adrenoceptor-mediated responses in perfused rat liver. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1220, 49-56.	1.9	7
67	Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study. <i>Haemophilia</i> , 0, , .	1.0	2